Group items tagged

Drug delivery means different methods, approaches, technologies, formulations, and systems for transporting a pharmaceutical compound in the body to achieve desired therapeutic effects. There are different types of drug delivery including intravenous injectable, inhalation, or absorption. The injectable drug delivery is considered the most effective route of administration for the effective delivery of drugs to the targeted sites. This enhances the patient's compliance with the drug. This method of drug delivery boosts the drug adsorption from various sites including intravenous, subcutaneous, and intramuscular. Moreover, it increases the bioavailability of the drug at the systematic circulation of the drug at the designated site of action. The challenges of administering an injectable drug to an area are unique and complex. It is common practice to inject a small amount of a drug into the skin of a subject in order to administer a larger dose. However, many complications could occur if too much of a drug is injected at once. Since most of these systems are designed to administer large amounts over a long period of time, multiple injections could cause serious health problems, such as infection and damage to vital organs. The future injectable drug delivery will require the development of new methods for delivering medications, and the creation of new products that provide a safer, more effective environment for the delivery process. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/injectable-drug-delivery-is-getting.html

Overview: Drug and device research is confusing and difficult on its own but when you start combining drugs with devices the regulatory landscape changes as there are more nuances to deal with. Knowing how drug and device studies are each regulated is important in navigating the challenges posed by studies that wish to use both. It is also important to be aware of current guidance affecting the use of both drugs and devices in a study as well current guidance affecting the classification of devices. Why should you attend: Information on drugs and devices is plentiful. But, it can also be daunting .The webinar will give attendees a foundation and a starting point on which they can build. Learning objectives: Define drug research Define device research Explore the differences between the two Describe requirements when drugs and devices are combined in one study Areas Covered in the Session: Defining Drug Research FDA approved drugs Investigational drugs Compassionate use Defining Device Research FDA approved devices 510 K devices Humanitarian Device Exemptions Invitro Diagnostic Devices Investigational Devices Federal regulations governing drugs and devices Guidance governing drugs and devices Combining devices and drugs into one study What are the requirements? What are the regulations and guidance? How these studies are reviewed Who Will Benefit: Investigators Researchers Research Staff Study Coordinators Auditors Research Administrators Speaker Profile Sarah Fowler-Dixon is Education Specialist and instructor with Washington University School of Medicine. She has developed a comprehensive education program for human subject research which has served as a model for other institutions. She crafted budgets, policies, procedures, reporting, and training for the new program. She has initiated the planning, development, authorship and implementation of many human subjects research policies, practices, guidelines, submission and reviewer forms often working with st

Pharmaceutical drug prices are rising and contribute significantly to total health expenditure worldwide. Since 2014, prescription drug prices have increased by 33%. In 2020, global spending on prescription drugs is expected to be US$ 1.3 trillion. Increasing drug prices and consumer spending on prescription drugs are increasing the demand for the pharmacy benefit management system. The system is operated by third-party administrators who act as a link between drug manufacturers, insurance providers, and pharmacists. The system assists in reducing drug prices by negotiating with drug manufacturers and retail pharmacies. Those who are enrolled in various health schemes and those without insurance can get the benefit of the pharmacy benefit management system. The system provides medicines at a lower price than those available at retail pharmacies. To reduce rising health expenses, Japan planned to start reviewing drug prices every year instead of every two years. The move reflects growing resistance to rising drug prices worldwide. In Europe, different approaches have been implemented to regulate drug prices. In Germany, manufacturers can freely set the prices of newly developed drugs during their first year on the market. Benefit assessments are done during this year and then used in price negotiations between manufacturers and the country's representatives of statutory health insurers. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/pharmacy-benefit-management-is-integral.html

Peptic ulcer drugs are medicines that are used to help fight and treat the symptoms of ulcers in stomach. These drugs, when taken regularly, can stop the production of certain hormones, such as pancreatic enzymes which are responsible for the digestion of foods. When the stomach produces too many enzymes, this can result in a painful ulcer. The first introduction of Peptic Ulcer Drugs was in the 1930s and it is still an important part of medical treatment today. Histological research on ulcers in patients who had undergone ulcer surgery showed that ulcers developed because of a reduced digestive system and inadequate absorption of nutrients in the intestines. The first Peptic Ulcer Drugs, introduced in the United States were drugs which helped to improve the absorption and metabolism of proteins and carbohydrates in the bloodstream. Other Peptic Ulcer Drugs include drugs that reduce the inflammation of the lining of the stomach and lower the levels of certain enzymes which can cause ulcer growth. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/the-rise-in-prevalence-of-peptic-ulcer.html

High potency active pharmaceutical ingredients are molecules widely used in the production of hormonal drugs which are used for the treatment of breast cancer. It is also used in the central nervous system drugs, cardiovascular drugs, and musculoskeletal drugs. Moreover, recently they have been also gaining demand in the gynecology & cosmetics industry. These drugs are segmented into innovative and generic. The growing prevalence of cancer is predominantly fueling the growth of the high potency active pharmaceutical ingredients market. The increasing number of the pharmaceutical industry coupled with the growing investment in the research and development activities conducted by the pharmaceutical industry is again contributing to the market growth. Moreover, increasing use of high potency active pharmaceutical ingredients as antibody-drug conjugates as it is one of the most important and effective treatments for cancer is also projected to augment the market growth. It is also used to treat glaucoma which is further anticipated to foster the growth of the high potency active pharmaceutical ingredients market. From the geographical point of view, North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence of chronic disease in the region. Read more @ https://sachinbhombe.blogspot.com/2021/03/high-potency-active-pharmaceutical.html

Overview: Many infectious diseases were historically confined to specific geographical regions. However, some now pose global threats due to ease of travel, globalization of trade and commerce and global warming. Government Agencies, non-Profit Organizations, Philanthropic groups and others are also funding vaccination programs for regions where infectious diseases are endemic and to deal with new outbreaks.. Such developments are stimulating research in and the development of improved vaccines, their manufacture and control. Supply Chain complexities and stability issues need to be addressed to cope with transport of vaccines to and their use in climatically hostile regions. Programs to address such challenges need to be implemented, being resourced by appropriately trained and qualified staff from a number of disciplines. Development programs for immuno oncology products also require staffing by similarly skilled professionals. Workers currently engaged in Discovery, Development and Manufacture of conventional medications , or those seeking career-change opportunities can develop an understanding of the concepts, constraints and opportunities associated with Vaccine products by attendance at the Webinar. Engineering professionals involved in facility construction, or repurposing can also benefit as can Regulatory Affairs Professionals or staff at medicines Evaluation Agencies. The subject matter is particularly suited to professionals who are expert in the various disciplines associated with conventional medications ("so-called "small molecules") who wish to expand and develop their skills by involvement in vaccine-related programs including immuno-oncology. Areas Covered in the Session: History of and development of vaccine concepts. undamentals of vaccination Vaccine Types Administration of Vaccines Future Concepts Immuno-Oncology Vaccine Manufacture Who Will Benefit: Regulatory Affair Managers Project Management Personnel QA Managers Scientists Technol

Disposable syringes are designed for one-time use and is discarded in order to prevent the spreading of infection. It can be defined as a sterile cylindrical medical instrument with a hollow needle at the end. This device act as a pump that easily draws drugs from vials and delivers these drugs to the body. A syringe is used to deliver injectable drugs in the body through an intravenous route. The growing use of injectable drugs across the healthcare sector is predominantly fueling the market growth of disposable syringes. The rise in global healthcare expenditure is another key factor propelling the market growth of disposable syringes. According to the World Health Organization, global spending on health was US$ 7.8 trillion in 2017 or about 10% of GDP and $1,080 per capita - up from US$ 7.6 trillion in 2016. Moreover, the growing demand for self-injection devices & long-acting formulations is again propelling the market growth. Increasing spending on R&D of new drugs development coupled with the growing demand for biologics will further favor the market growth of disposable syringes. Furthermore, growing concerns regarding needle stick injuries and accidental infections are also expected to bolster the market growth of disposable syringes. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/11/increasing-spending-on-r-of-new.html

In order to become a safe and effective medicine, a compound has to travel through a lengthy process of rigorous testing. Over the last few decades, the amount of time required to develop and test a novel drug has increased drastically. However, the introduction of social media and digital technology into drug development have the ability to significantly expedite this process. This webinar will explore the policies and principles of using social media through the evolution of developing a pharmaceutical drug from its initial stages to its introduction into the market. This includes analyzing the methods in which pharmaceutical companies utilize social media during the planning process, identifying the best candidate for the lead compound in a drug, conducting animal and human testing, recruiting candidates for clinical trials.

Overview: The connection between the Body, its physiology and particularly biochemistry, have been linked to the mind with particular emphasis upon emotions and stress. This can be easily substantiated in common everyday situations. Anyone who has observed a facial red flush triggered by some sort of embarrassment can attest to the foregoing connection. The emotions and stress play a key role in many if not all diseases and disorders: due to the vastness of the subject, we will focus on the application of the mind/body connection(MBC) to skin. This serves as an introduction to the field of psych dermatology which, although still in its infancy in the USA, is expanding as evidence with regard to the psychological component related to the etiology of skin diseases continues to grow. Concurrently, the field of Alternative techniques IN mind/body treatments continue to grow in leaps and bounds providing effective methods for integration with conventional cosmetic and dermaceutical treatment. This provides a dual complimentary pathway both for prevention and treatment of any/most skin disorders. Expanding on this model, we have already shown how the mind influences the body as per the above example. This general proposition can be extended to include specific skin disorders such as acne rosacea psoriasis eczema and atopic dermatitis to name a few. We will concentrate on Acne for the sake of this discussion. First, focusing on the B component of the BMC model, the primary lesion associated with acne is the formation microcomodones, which are small enough to proceed undetected until larger comodones appear later in the cycle. The latter cycle is initiated by peroxidation of squalene and unsaturated fatty acids present in human sebum. This leads to the foregoing lesions and pro- inflammatory mediators such as cytokines and interleukins followed by an increase of p.acnes on the epithelial cell wall together with increased film formation of the p.acnes is the same area This

Multiple myeloma is a type of cancer that forms a type of white blood cell called a plasma cell. In multiple myeloma, cancerous plasma cells gather around the bone marrow and crowd out healthy cells. Some of the most common symptoms of multiple myeloma are pain in the back or bones, anemia, fatigue, and kidney damage. Multiple myelomas can be identified by a biopsy, which is conducted when tissue samples from the affected area are taken and examined under a microscope. When multiple myelomas are detected on an examination, it is typically very easy to remove them with a scalpel, and in many cases, surgeons will opt to remove only one lobe of tissue at a time. There has the development of various multiple myeloma drugs over the years with key industry players being involved in continuous research and development activities. Selinexor is one of the latest U.S. FDA-approved drug for multiple myeloma and is used to treat people suffering from relapsed or refractory disease. Furthermore, Ixazomib is the first and only oral proteasome inhibitor, indicated for multiple myeloma treatment. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/multiple-myeloma-drugs-are-getting.html

"""Pancreatic Cancer Drug Pipeline Analysis""Pancreatic Cancer Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. "

Metastatic osteosarcoma is one form of the disease osteoarthritis. It has been found that this disease occurs due to a problem with the cells in the spinal cord that are responsible for the proper function of the joints. The disease generally affects the aging group and those individuals suffering from other medical conditions like diabetes etc. The pain caused due to metastatic osteosarcoma can be so severe that it leads to tremendous disability to the affected person. Increasing drug pipeline for malignant bones and soft tissue cancer is expected to drive growth of the global metastatic osteosarcoma treatment market. Key biopharmaceutical and pharmaceutical companies are focused on research and development activities to synthesize novel drug treatment for soft tissue and malignant bone cancer. For instance, in September 2020, Junshi Biosciences, a major biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) Orphan Drug designation to Toripalimab for the treatment of soft tissue sarcoma. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/metastatic-osteosarcoma-treatment.html

The growing incidence of viral conjunctivitis cases is driving the growth of the viral conjunctivitis drugs market. According to National Center for Biotechnology: 2017, adenovirus is the most common cause of viral conjunctivitis and up to 70% of cases of acute conjunctivitis are viral. The number of individuals affected by viral conjunctivitis is estimated to be as high as 15 to 20 million per year in the U.S. Additionally, a rising number of research and development activities for enhancing the effectiveness of viral conjunctivitis drugs is again projected to accelerate the growth of the market. For instance, in 2019, iVIEW Therapeutics Inc., a clinical-stage ophthalmology drug development company, announced the dosing of the first patient in Phase II clinical trial. iVIEW Therapeutics Inc. is testing the safety and efficacy of the IVIEW-1201 in patients (age ≥15 years) for the treatment of acute adenoviral conjunctivitis. In 2018, Starpharma Holdings Limited, a company headquartered in Australia, received a patent for SPL7013 ophthalmic drops for viral conjunctivitis from the U.S. Patent and Trademark Office. The patent has been granted to the company due to its broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis, and other eye infections. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/08/starpharma-holdings-limited-received.html

Epilepsy also referred to as a seizure disorder in which nerve cell activity in the brain is disturbed causing seizures. Over 50 million cases of epilepsy are observed across the globe with 80% of them living in emerging economies. Generally, epilepsy is treated by medication, while some cases require surgery, devices, or dietary changes. Over the years, various antiepileptic drugs have been approved and introduced in the market. Each new antiepileptic medication is well tolerated and shows statistically significant improvements in seizure frequency over time compared to pretreatment. However, these medications each carry their own set of challenges and limitations that must be addressed to patients taking them. Carbamazepine, a member of the benzodiazepine class, is antiepileptic drugs used to treat patients with symptomatic epilepsy and other forms of non-epilepsy epilepsy. It is typically administered intravenously or intramuscularly. Patients must be carefully monitored for allergic reactions and heart and blood pressure effects. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/antiepileptic-drugs-are-getting-better.html

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.

Rationale for Clinical Trial Regulations Clinical trials, as we all know, are carried out to test the efficacy of a new drug or device being developed for a specific condition or disease. Clinical trials are experiments that have a high degree of risk if they are not properly implemented. For this reason, it is necessary for regulatory bodies to regulate clinical trials. The core rationale for regulating the various stages of clinical trials is that human subjects, who are part of the research, have to be protected. These clinical trial regulations are legislated at all stages: local, State, national and international. Clinical trial regulations are in force in different countries of the world. Common clinical trial regulations are also made globally by the International Conference on Harmonization (ICH), which has the mandate of setting out good practices for clinical trial regulations for trials done in global cooperation. These regulations cover the administrative, procedural and ethical aspects of clinical trials. Briefly, these are the areas in which there are clinical trial regulations for each of these aspects of clinical trials: Administrative: The administrative aspects of clinical trial regulations pertain to the way the clinical trials are run, and the way they are tracked and monitored throughout their lifecycle. A clinical trial is usually monitored by a sponsoring company or a Contract Research Organization (CRO), which the former hires at times for reasons of convenience and cost cutting. Clinical trial regulations in this area is obviously of importance because if something goes wrong at any administrative stage; these can be rectified. Procedural: Procedural aspects of clinical trial regulations relate to ways by which subjects are chosen for a clinical trial. Proper care has to be taken to ensure that the subjects are appropriate for the clinical study, are from the prescribed age, geographical, demographic, racial and gender-related cl

Hepatitis and Hepatitis C are two of the most common forms of hepatitis and both are caused by different viral strains. Various companies are involved in developing a new drug for treating Hepatitis C due to the growing patient pool. The disease is caused by a virus that can be transmitted from person to person and can be acquired either through ingesting an infected person's blood or inhaling their infected air. Hepatitis is caused by a strain of the virus which is not transmitted from one person to another and is caused by a genetic defect. Hepatitis is caused by the human papillomavirus (HPV), while hepatitis C is caused by a variety of different strains of the virus called HCV. Hepatitis can be caused by a single strain of the virus, although some cases have been known to be caused by multiple strains. It is also possible for a person to contract one form of the virus, then develop a secondary infection which is caused by another form of the virus. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/hepatitis-c-drug-is-gaining-prominence.html

Biopharmaceuticals contract manufacturing refers to pharmaceutical companies outsourcing the development and manufacturing of drugs. It is driven by the use of advanced technologies, scientific advances, and d a highly complex research and development enterprise. It provide wide range of manufacturing services to biopharmaceutical companies. Biopharmaceutical contract manufacturing is widely used due to the complexity in manufacturing of biomolecules, as are considerably more complex, different in shape, size, and behavior than pharmaceuticals. Contract manufacturing organizations (CMOs) provide services from development of biologics to commercial scale production. Biopharmaceutical contract manufacturing involves the production of medicines in small units that can be customized to meet customer specifications. Contract manufacturers usually produce high quality and highly secure pharmaceuticals at low prices. The primary components of these drugs are plant materials and chemical substances. Biopharmaceutical companies are focused on producing numerous pharmaceuticals for the pharmaceutical industry. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2021/03/biopharmaceutical-contract.html